Table 2. Clinicopathological correlation of β-catenin expression in endometrial cancer tissue array (EMC1501) (Pantomics, CA, USA).
| Characteristics | Total | β-catenin expression (fold change) | ||
|---|---|---|---|---|
| < 2.7 folds | > 2.7 folds | p | ||
| All cases | 120 | 58 (48.3%) | 62 (51.7%) | |
| Stage | ||||
| Early (1) | 84 | 44 (52.3%) | 40 (47.7%) | |
| Late (2+3) | 34 | 14 (41.2%) | 20 (58.8%) | 0.313 |
| Grade | ||||
| Low (1+2) | 66 | 37 (56.1%) | 29 (43.9%) | |
| High (3) | 40 | 14 (35.0%) | 26 (65.0%) | 0.045* |
| Lymph Node Metastasis | ||||
| Absence | 95 | 50 (52.6%) | 45 (47.4%) | |
| Presence | 23 | 8 (34.8%) | 15 (65.2%) | 0.164 |
| CyclinD1 | ||||
| <2.5 folds | 56 | 38 (67.9%) | 18 (32.1%) | |
| >2.5 folds | 64 | 20 (31.3%) | 44 (68.7%) | <0.001* |
| FGF9 | ||||
| <3.0 folds | 51 | 33 (64.7%) | 18 (35.3%) | |
| >3.0 folds | 69 | 25 (36.2%) | 44 (63.8%) | 0.003* |